Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 29,800 shares, a growth of 57.7% from the March 31st total of 18,900 shares. Based on an average daily volume of 8,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright lowered their target price on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, March 4th. StockNews.com initiated coverage on Aethlon Medical in a research note on Saturday, April 20th. They issued a “sell” rating for the company.

Aethlon Medical Stock Performance

Aethlon Medical stock opened at $1.37 on Friday. The stock has a market capitalization of $3.59 million, a price-to-earnings ratio of -0.27 and a beta of 1.88. Aethlon Medical has a 52-week low of $1.33 and a 52-week high of $5.00. The stock’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $1.75.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). On average, equities research analysts forecast that Aethlon Medical will post -4.98 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.